ES
MARKETS / NASDAQ / PROF
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Profound Medical Corp. PROF

3 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$16.1M
▲ 50.7% vs FY2024
EPS · FY25
$-1.41
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-67.1%
Net margin · FY25
-264.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 16.1M
Revenue, FY2025 · full 3-year series below
Revenue Net income
0.0050.010.0150.020.0-0.020232025
0.0050.010.0150.020.0-0.020232025

The company lost 264 cents on every revenue dollar this year.

Per share
USD -1.41
Diluted EPS, FY2025
EPS
0.40.81.2-1.4120232025
0.40.81.2-1.4120232025

The company pays no cash dividend.

Profitability
-67.1%
Return on equity, FY2025
ROE
0.250.50.751-67.1%20232025
0.250.50.751-67.1%20232025
Operating margin-256.3%
Net margin-264.4%
Return on assets-57.6%

Each USD of equity lost 67 cents this year.

Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.04B
Shares outstanding, FY2025
0.020.0420232025
0.020.0420232025
Change, 5 years—
Change, 10 years—

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 77.5M
total assets, end of FY2025
Total assetsUSD 77.5M
EquityUSD 66.4M
CashUSD 59.7M
Gross debtUSD 4.5M
Net debtUSD -55.2M
Current ratio12.52×

The company holds more cash than debt.

History
3 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
Revenue $B
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
Income tax $B
0.0
−0.0
−0.0
Net income $B
−0.0
−0.0
−0.0
EPS, diluted $
−1.41
−1.12
−1.34
Dividend / sh $
·
·
·
Payout %
·
·
·
ROE %
−67.1
−60.7
−90.7
Shares out B
0.04
0.03
0.02

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
12 of 12
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed